Residex launches Health Capital II

Fund

Residex has launched its fourth vehicle, Health Capital II. It has recently started fundraising with a target set between EUR45-60m entailing a EUR15m participation by the Dutch insurer Achmea. The fund will have a lifespan of eight to 10 years.

Residex Group also invests through Health Innovation Fund in ventures and through Life Science Partners in biotechnology, both in the Netherlands.

Investors

Residex is looking for four investors who will be willing to subscribe to a minimum of EUR10m each and who will be interested in the health sector. Achmea has already subscribed to EUR15m. Residex will privilege strategic investors and banks.

Investments

The fund will target companies in the healthcare sector that already generate turnover, with a potential of approximately EUR20m. The fund plans to specialise in a buy-and-build strategy. Investments are limited to the Benelux region where there are many small companies in the health sector.

The transaction value will range between EUR2-8m, while the investors will seek to acquire large minority stakes. Co-investment is possible, but not desired.

Investments in the healthcare are long-term investments. It is possible that the fund will seek to exit its whole portfolio at once, if it achieves its aim of creating a network between its portfolio companies.

People

The fund will be managed by the Residex team.

Name: Health Capital II

Target: EUR45-60m

Launched: April 2008

Focus: Buyout, Benelux, healthcare

Contact

Bart Peletier

Address

Van Golsteinlaan 26

Postbus 1345

7339 GTApeldoorn

The Netherlands

Tel: +31 (0)55 5260800

Fax: +31 (0)55 5260808

peletier@residex.nl.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Venture
• Benelux